Eczema Free Forever™

Mar 15, Sanofi’s Dupilumab Joins UK’s Early Access Scheme

Patients with atopic dermatitis are to get early access to Sanofi’s dupilumab before it is given marketing authorisation in the UK. This is after some positive research results were received from testing. It will be available to adult patients who have severe atopic dermatitis that has not responded to, or are unable to use, other treatments.
Eczema Blog

Eczema Free Forever™